ARTICLE: A Machine-Based Learning Model for Recurrence Prediction and Timing After Endoscopic Eradication Therapy for Barrett's Esophagus
AUTHORS: Venkata Akshintala, Samuel Han, Yukun Yan, Raf Bisschops, Case Brennan, Yanna Cai, D Chamil Codipilly, Cary Cotton, Dayna Early, Steven A Edmundowicz, Swathi Eluri, Jazmyne Gallegos, Rohit Goyal, Hazem T Hammad, Rehan Haidry, Thomas Hollander, Khalid Husain, Prasad G Iyer, Justeena Jojo, Vladimir Kushnir, Srinadh Komanduri, Cadman Leggett, Laurence Lovat, V Raman Muthusamy, Amit Rastogi, Stefan Seewald, Nicholas J Shaheen, Adarsh Thaker, Kornpong Vantanasiri, Craig Jones, Sachin Wani
JOURNAL: Clin Gastroenterol Hepatol. 2026 Apr 7:S1542-3565(26)00236-3. doi: 10.1016/j.cgh.2026.03.026. Online ahead of print.
Abstract
Background & aims: Tools that can predict recurrence in patients with Barrett's esophagus (BE)-related neoplasia treated with endoscopic eradication therapies (EET) to guide surveillance decisions are needed. We aimed to develop and validate a machine learning (ML)-based prediction tool to predict the risk and timing of recurrence status post EET.
Methods: Three prospective United States databases of patients who underwent EET for BE-related neoplasia and achieved complete eradication of intestinal metaplasia (CE-IM; n = 1114) were utilized to develop and internally validate a ML-based prediction tool using the Random Forest model and imputation techniques. Predictors incorporated in this model included demographics, endoscopy and pathology results, and EET details. A Cox proportional hazards model was utilized to predict the time to recurrence. External validation was performed using the United States Radiofrequency Ablation database (n = 1397).
Results: BE recurrence occurred in 29.2% (n = 734) of patients and BE-related neoplasia recurrence in 10.6% (n = 265), with a mean time to recurrence of 21.3 months (mean follow-up, 37.7 months). The top predictors for recurrence included BE length, body mass index, age, sessions needed to achieve CE-IM, and baseline histology. The model was well-calibrated, and area under the receiver operating characteristic curve (AUC) was 0.92 (95% confidence interval [CI], 0.85-0.95) on internal validation and 0.91 (95% CI, 0.87-0.95) on external validation for BE recurrence. For BE-related neoplasia recurrence, the AUC was 0.90 (95% CI, 0.88-0.93). The model had moderate discriminative performance to predict timing of recurrence with a C-index of 0.701 at 1 year (AUC 0.71), 0.68 (AUC 0.69) at 3 years, and 0.66 (AUC 0.69) at 5 years.
Conclusions: This United States-based externally validated tool accurately predicts BE and BE-related neoplasia recurrence and timing post EET. This practical tool may help provide a personalized approach to surveillance strategies.
For the full article, click here.
For a link to the abstract, click here.
Medscape: Machine Learning Model Predicts Recurrence of Barrett's Esophagus
